OPRX
OptimizeRx Corporation
NASDAQ · Healthcare · Medical - Healthcare Information Services · US
$7.87
−1.01%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 98.7M | 109.4M | 92.1M | 71.5M | 62.5M |
| Cost of Revenue | 27.5M | 40.2M | 32.7M | 28.6M | 23.5M |
| Gross Profit | 71.2M | 69.3M | 59.4M | 42.9M | 39.0M |
| Operating Expenses | |||||
| R&D Expense | 6.8M | — | — | — | — |
| SG&A Expense | 45.9M | 50.2M | 61.3M | 58.0M | 49.2M |
| General & Admin Expense | 35.6M | 50.2M | 61.3M | 58.0M | 49.2M |
| Selling & Marketing Expense | 10.3M | — | — | — | — |
| Other Expenses | 7.2M | 7.0M | 11.8M | 11.3M | 2.0M |
| Total Operating Expenses | 59.9M | 57.2M | 73.1M | 69.3M | 51.3M |
| Cost and Expenses | 87.4M | 97.4M | 105.8M | 97.9M | 74.7M |
| Operating Income (EBIT) | 11.3M | 12.1M | (13.7M) | (26.4M) | (12.3M) |
| Non-Operating | |||||
| Interest Income | 333.0K | 353.0K | 329.0K | 2.2M | 852.3K |
| Interest Expense | 4.7M | 5.3M | 6.2M | 1.5M | — |
| Net Interest Income | (4.3M) | (4.9M) | (5.8M) | 738.0K | 852.3K |
| Other Non-Op Income/Expense | (4.5M) | (5.1M) | (5.7M) | 1.2M | 852.3K |
| Non-Operating Income (excl Interest) | (162.0K) | (183.0K) | (481.0K) | (2.7M) | (852.3K) |
| EBT (Pre-Tax Income) | 6.8M | 7.0M | (19.4M) | (25.2M) | (11.4M) |
| Income Tax Expense | 2.2M | 1.8M | 725.0K | (7.6M) | — |
| Bottom Line | |||||
| Net Income | 4.6M | 5.1M | (20.1M) | (17.6M) | (11.4M) |
| Earnings from Cont. Ops | 4.6M | 5.1M | (20.1M) | (17.6M) | (11.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 4.6M | 5.1M | (20.1M) | (17.6M) | (11.4M) |
| Per Share | |||||
| Basic EPS | $0.24 | $0.28 | ($1.10) | ($1.03) | ($0.64) |
| Diluted EPS | $0.23 | $0.27 | ($1.10) | ($1.03) | ($0.64) |
| Revenue Per Share | $5.25 | $5.90 | $5.04 | $4.18 | $3.51 |
| Shares | |||||
| Basic Shares Outstanding | 18.8M | 18.6M | 18.3M | 17.1M | 17.8M |
| Diluted Shares Outstanding | 18.8M | 19.0M | 18.3M | 17.1M | 17.8M |
| Profitability Metrics | |||||
| EBITDA | 15.6M | 16.6M | (8.9M) | (21.3M) | (9.4M) |
| D&A | 4.1M | 4.3M | 4.3M | 2.4M | 2.0M |
| EBIT | 11.5M | 12.2M | (13.2M) | (23.7M) | (11.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026